Recent phase III studies, BRUIN CLL-313 and CLL-314, have established pirtobrutinib, a noncovalent Bruton tyrosine kinase (BTK) inhibitor, as a candidate for first-line therapy in chronic lymphocytic leukemia (CLL). These trials underpin the consideration of pirtobrutinib earlier in the disease course. Regulatory developments noted in the source include approval in the European Union for an all-lines indication for pirtobrutinib.
The position of pirtobrutinib as a potential first-line option represents a meaningful shift from prior practice where covalent BTK inhibitors commonly anchor initial therapy and provide a validated route into later-line management when relapse occurs.
The correspondence highlights an important and currently untested asymmetry in sequencing data. Published evidence demonstrates that pirtobrutinib retains activity after failure of covalent BTK inhibitors. In contrast, there are no clinical data reported on the activity or outcomes of covalent BTK inhibitors when used after failure of first-line pirtobrutinib. This lack of reverse-sequence data creates uncertainty about how best to manage relapse following initial noncovalent BTK inhibition.
Because covalent BTK inhibitors are the class that currently anchors relapse management, the absence of evidence for their effectiveness post-pirtobrutinib is clinically relevant for sequencing decisions, particularly in patients expected to require multiple lines of therapy.
The authors note that resistance to first-line pirtobrutinib can emerge through kinase-domain mutations in BTK. Examples cited include mutations such as A428D and L528W. In vitro data indicate that these specific kinase-domain changes can confer cross-resistance to covalent BTK inhibitors. Thus, mutations arising under selective pressure from pirtobrutinib may compromise the activity of the covalent agents that clinicians currently rely on for relapse treatment.
The existence of such mutations and their demonstrated in vitro cross-resistance underlines the biological plausibility of clinically meaningful loss of utility for covalent BTK inhibitors after pirtobrutinib exposure. However, the correspondence is careful to point out the distinction between in vitro cross-resistance signals and verified clinical outcomes.
A central point of the correspondence is that no clinical data exist addressing outcomes with covalent BTK inhibitors administered after pirtobrutinib failure. The authors explicitly state that this reverse-sequence evidence is absent from the literature and from reported trial results. Because of this, the true impact of pirtobrutinib-first sequencing on subsequent lines of therapy—particularly the effectiveness of covalent BTK inhibitors when used later—remains unknown.
This evidence gap is not framed as a definitive contraindication to first-line pirtobrutinib but rather as an area of uncertainty that affects long-term strategy for patients likely to need several treatments over the course of disease.
Given the asymmetry in available evidence, the authors propose several practical, evidence-aligned measures to manage uncertainty while preserving therapeutic options for patients:
Consider a cautious approach that retains the clinically validated covalent-first sequence for patients who are expected to require multiple lines of therapy, until data on the reverse sequence are available.
Implement mutation testing at progression to detect kinase-domain changes (for example, A428D, L528W) that may affect the choice and expected efficacy of subsequent BTK-targeted agents.
Establish registry-based tracking of outcomes for patients treated with pirtobrutinib, particularly those who receive covalent BTK inhibitors afterward, to collect real-world reverse-sequence data.
Ensure that forthcoming guideline updates explicitly address sequencing questions and the current evidence limitations so that clinicians and patients can make informed shared decisions.
These recommendations emphasize surveillance and evidence collection rather than prescriptive exclusion of pirtobrutinib from first-line consideration.
The correspondence argues for prudence in adopting first-line pirtobrutinib broadly, not because the agent lacks activity, but because of an asymmetric evidence base: pirtobrutinib is validated after covalent BTK inhibitor failure, while covalent agents have not been clinically evaluated after pirtobrutinib. The potential for kinase-domain mutations induced by pirtobrutinib that confer in vitro cross-resistance to covalent BTK inhibitors further motivates a careful sequencing strategy for patients likely to need multiple therapy lines.
Until clinical data on the reverse sequence are reported, the authors recommend retaining the validated covalent-first approach for appropriate patients, performing mutation testing at progression, tracking post-pirtobrutinib outcomes in registries, and making sequencing an explicit topic in guideline revisions.
The source bases these recommendations on trial results, regulatory developments, and mechanistic resistance data; it also notes the absence of clinical reverse-sequence outcomes as the key limitation informing their cautious stance.